ClōSYS | COVID-19 Virus

ClōSYS Ultra Sensitive Rinse, ClōSYS Sensitive Rinse, & ClōSYS Oral Spray Lab Tested on COVID-19 virus

Because the COVID-19 virus can be transmitted from spray droplets from the mouth, oral care companies are being asked if their products help reduce the spread of this virus. So we're working to learn more. - View Press Release

As ClōSYS is an excellent antimicrobial for oral care we initiated the first step lab tests to understand if our patented formula might be helpful reducing the viral load of saliva thus potentially lowering the transmission of the COVID-19 virus. Further studies in the mouth are needed and in progress.

NOTE: CloSYS Products have NOT been proven to help mitigate, prevent, treat diagnose or cure the COVID-19 virus. Lab tests are just the first steps in learning more.

View Lab Studies

CloSYS Press Release 2020

Lab Tests: ClōSYS Oral Rinse Eliminated COVID-19 Virus up to 98.4% in 30 Seconds

SCOTTSDALE, Ariz. (Aug. 31, 2020) -- Rowpar Pharmaceuticals Inc., the makers of the ClōSYS brand of toothpastes, mouthwashes and oral sprays, announced today that an in vitro laboratory analysis showed that ClōSYS Ultra Sensitive Oral Rinse reduced SARS-CoV-2 (COVID-19 virus) up to 98.4% within 30 seconds without the use of any harsh chemicals like alcohol, hydrogen peroxide or povidone iodine.

The study of ClōSYS Ultra Sensitive Oral Rinse was conducted at MRIGlobal, an independent laboratory in Kansas City that is accredited to test highly infectious viruses like SARS-CoV-2, the virus that causes the COVID-19 disease. A second independent accredited lab, Microbac Laboratories, Inc. in Sterling, Va. provided similar results. The studies can be found at Clō

These initial trials did not include testing the oral cavity, but based on these results, Rowpar has launched additional studies to determine whether ClōSYS over-the-counter products can help lower the transmission of the novel coronavirus from one person to another.

“These are exciting and potentially groundbreaking findings,” said CEO of Rowpar Pharmaceuticals Jim Ratcliff. “We know that the COVID-19 virus can be transmitted from person to person through spray droplets from the mouth, so this is an important first step in determining whether our oral care products can make a significant impact in reducing the chances of becoming ill or infecting others. There is a lot more to learn as we follow the science, but it’s a very positive start for our rinse formula.”

While there is no evidence that inactivating the COVID-19 virus in the mouth will impact disease transmission, the studies reinforce the antimicrobial strength of ClōSYS products. Clinical trials in progress at the University of California San Francisco are evaluating whether oral rinses can reduce the viral load in the mouth, which may in turn reduce the transmission of the disease.

All ClōSYS products contain a proprietary formula with Clorastan®, the trade name for stabilized chlorine dioxide, which is a safe and effective oxidant long recognized for its antimicrobial, disinfecting and sanitizing properties. The ClōSYS formula is naturally activated by acids in saliva. Once released, Clorastan® disrupts and penetrates dental biofilm, killing the microbial pathogens living within and inhibiting their re-growth.


ClōSYS | COVID-19 Virus FAQ's

With studies come more questions.  It is our hope that with additional research we will be able to answer these and other questions in greater detail.

We have a lot more to learn as a company whose mission is to help people get well and stay well through better oral health. It starts with honesty, transparency, and following the science.

US Provisional Patent Application Nos. 63,061,019 and 63,071,589 (2020)

Covid-19 FAQs